



## **News Release**

---

### **ABRAXIS BIOSCIENCE TO PRESENT AT LAZARD MARKETS HEALTHCARE CONFERENCE**

**LOS ANGELES, Calif., – (November 26, 2007)** – Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, today announced that Patrick Soon-Shiong, M.D., chairman and chief executive officer of Abraxis BioScience, will present a company overview at the Lazard Capital Markets Fourth Annual Healthcare Conference on Wednesday, November 28, 2007 at 8:30 a.m. ET at the New York Palace Hotel in New York City.

Interested parties can listen to the presentation through a live webcast at the Abraxis BioScience Web site, [www.abraxisbio.com](http://www.abraxisbio.com). Listeners are encouraged to visit the Web site at least 15 minutes prior to the start of the scheduled presentation to register, download and install any necessary audio software. For those unable to listen to the live webcast, the presentation will be archived on the same Web site for approximately 14 days.

#### **About the new Abraxis BioScience**

Abraxis BioScience is a fully integrated biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients and medical professionals safer and more effective treatments for cancer and other critical illnesses. The Abraxis portfolio includes the world's first and only protein-based nanoparticle chemotherapeutic compound (ABRAXANE) which is based on its proprietary tumor targeting system known as the *nab*<sup>TM</sup> technology platform. From the discovery and research phase to development and commercialization, Abraxis BioScience is committed to rapidly enriching the company's pipeline and accelerating the delivery of breakthrough therapies that will transform the lives of the patients who need them. Abraxis, with headquarters in Los Angeles, California, trades on the Nasdaq Global Market under the symbol "ABII". For more information about the company and its products, please visit [www.abraxisbio.com](http://www.abraxisbio.com).

###

#### **Contact**

Investors and Media:  
Christine Cassiano, (310) 633-9495